Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Durable hematological and major cytogenetic response in a patient with isolated 20q deletion myelodysplastic syndrome treated with lenalidomide.

Jana B, Khanfar A, Ninan M.

Case Rep Oncol Med. 2014;2014:949515. doi: 10.1155/2014/949515. Epub 2014 Feb 12.

3.

Durable response to lenalidomide in a patient with myelodysplastic syndrome associated with isolated 5q deletion and JAK2 V617F mutation despite discontinuation of treatment.

Hatzimichael E, Lagos K, Vassou A, Gougopoulou D, Papoudou-Bai A, Briasoulis E.

Mol Clin Oncol. 2016 Jul;5(1):23-26. Epub 2016 Apr 20.

4.

Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes.

Komrokji RS, List AF.

Ann Oncol. 2016 Jan;27(1):62-8. doi: 10.1093/annonc/mdv488. Epub 2015 Oct 26. Review.

5.

Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study.

Giagounidis A, Mufti GJ, Mittelman M, Sanz G, Platzbecker U, Muus P, Selleslag D, Beyne-Rauzy O, te Boekhorst P, del Cañizo C, Guerci-Bresler A, Nilsson L, Lübbert M, Quesnel B, Ganser A, Bowen D, Schlegelberger B, Göhring G, Fu T, Benettaib B, Hellström-Lindberg E, Fenaux P.

Eur J Haematol. 2014 Nov;93(5):429-38. doi: 10.1111/ejh.12380. Epub 2014 Jun 9.

6.

Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.

Stahl M, Zeidan AM.

Cancer. 2017 Feb 13. doi: 10.1002/cncr.30585. [Epub ahead of print] Review.

PMID:
28192601
7.

High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide.

Jonasova A, Bokorova R, Polak J, Vostry M, Kostecka A, Hajkova H, Neuwirtova R, Siskova M, Sponerova D, Cermak J, Mikulenkova D, Cervinek L, Brezinova J, Michalova K, Fuchs O.

Eur J Haematol. 2015 Jul;95(1):27-34. doi: 10.1111/ejh.12457. Epub 2014 Oct 31.

PMID:
25284710
8.

Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.

Göhring G, Giagounidis A, Büsche G, Kreipe HH, Zimmermann M, Hellström-Lindberg E, Aul C, Schlegelberger B.

Ann Hematol. 2010 Apr;89(4):365-74. doi: 10.1007/s00277-009-0846-z. Epub 2009 Oct 24.

PMID:
19855965
9.

Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies.

Giagounidis AA, Germing U, Aul C.

Clin Cancer Res. 2006 Jan 1;12(1):5-10. Review.

10.

Myelodysplastic Syndrome with concomitant t(5;21)(q15;q22) and del(5)(q13q33): case report and review of literature.

Kasi Loknath Kumar A, Weckbaugh B, Sirridge C, Woodroof J, Persons D, Kambhampati S.

Stem Cell Investig. 2016 Feb 23;3:3. doi: 10.3978/j.issn.2306-9759.2016.02.01. eCollection 2016 Feb 23.

11.

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ, Dreisbach L, Schiffer CA, Stone RM, Greenberg PL, Curtin PT, Klimek VM, Shammo JM, Thomas D, Knight RD, Schmidt M, Wride K, Zeldis JB, List AF.

Blood. 2008 Jan 1;111(1):86-93. Epub 2007 Sep 24.

12.

[Lenalidomide treatment in myelodysplastic syndrome with 5q deletion--Czech MDS group experience].

Jonášová A, Červinek L, Bělohlávková P, Čermák J, Beličková M, Rohoň P, Černá O, Hochová I, Šišková M, Kačmářová K, Janoušová E.

Vnitr Lek. 2015 Dec;61(12):1028-33. Czech.

PMID:
26806497
13.

Long-Term Response in a Patient with del(5q) Myelodysplastic Syndrome Who Discontinued Lenalidomide and Obtained a Good Response and Tolerance to Rechallenge.

Pisani F, Orlandi G, Merola R.

Case Rep Oncol. 2014 Apr 25;7(1):277-84. doi: 10.1159/000362643. eCollection 2014 Apr 25.

14.

PP2A: The Achilles Heal in MDS with 5q Deletion.

Sallman DA, Wei S, List A.

Front Oncol. 2014 Sep 23;4:264. doi: 10.3389/fonc.2014.00264. eCollection 2014 Sep 23. Review.

15.

Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes.

Abou Zahr A, Saad Aldin E, Komrokji RS, Zeidan AM.

J Blood Med. 2014 Dec 22;6:1-16. doi: 10.2147/JBM.S50482. eCollection 2014 Dec 22. Review.

16.

Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes.

List A.

Clin Lymphoma Myeloma. 2009;9 Suppl 3:S302-4. doi: 10.3816/CLM.2009.s.028. Review.

PMID:
19778857
17.

Telomere dynamics in patients with del (5q) MDS before and under treatment with lenalidomide.

Beier F, Masouleh BK, Buesche G, Ventura Ferreira MS, Schneider RK, Ziegler P, Wilop S, Vankann L, Gattermann N, Platzbecker U, Giagounidis A, Götze KS, Nolte F, Hofmann WK, Haase D, Kreipe H, Panse J, Blasco MA, Germing U, Brümmendorf TH.

Leuk Res. 2015 Sep 21. pii: S0145-2126(15)30380-5. doi: 10.1016/j.leukres.2015.09.003. [Epub ahead of print]

PMID:
26427727
18.

Physician Education: Myelodysplastic Syndrome.

Yoshida Y.

Oncologist. 1996;1(4):284-287.

19.

Complete Remission of del(5q) Myelodysplastic Syndrome after 7 Days of Lenalidomide Therapy Gives an Alert!

Al-Jafar HA, Al-Azmi S, Qassem JA, Hasan EA, Alduaij A.

Case Rep Oncol. 2012 Sep;5(3):586-91. doi: 10.1159/000345098. Epub 2012 Oct 30.

20.

De novo myelodysplastic syndrome (MDS) with deletion of the long arm of chromosome 20: a subtype of MDS with distinct hematological and prognostic features?

Wattel E, Laï JL, Hebbar M, Preudhomme C, Grahek D, Morel P, Bauters F, Fenaux P.

Leuk Res. 1993 Nov;17(11):921-6. Review.

PMID:
8231232

Supplemental Content

Support Center